Infectious Disease Therapeutics Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc.
- Merck & Co.
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Sun Pharma Industries Ltd.
- Cipla Ltd.
The strong presence and result-driven approach toward an effective healthcare system across the globe by pharmaceutical companies is shaping the environment for the infectious disease therapeutics market. Key players are focused on developing novel drugs and therapeutics to cater to rising burden of various infectious diseases. Some research institutes are also partnering with companies to assist in R&D projects while some companies are adopting several techniques such as mergers and acquisitions, joint ventures, product launches, and license agreements to enhance their product base and retain their market position. Here are some leading key players operating in the infectious disease therapeutics market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of infectious disease therapeutics is estimated at USD 138.77 billion.
The global infectious disease therapeutics market size crossed USD 134.06 billion in 2025 and is likely to register a CAGR of around 3.9%, exceeding USD 196.54 billion revenue by 2035.
North America’s infectious disease therapeutics market is anticipated to capture 42.1% share by 2035, driven by aging population and strong research and development infrastructure.
Key players in the market include Pfizer Inc, GlaxoSmithKline, plc, Merck & Co., F. Hoffmann-La Roche Ltd, AstraZeneca, Mylan N.V., Novartis AG, Sanofi.
